Bio-transistor firm looks to accelerate mass production

January 14, 2021 //By Rich Pell
Bio-transistor firm looks to accelerate mass production
Graphene-based digital biosensor company Cardea Bio has announced a $6.5 million series A extension that brings the A round total above $20 million.

The company, which integrates molecular biology with semiconductors via graphene-based biology-gated transistors, says the new capital infusion was led by the life sciences and biotechnology focused investor 3E Bioventures Capital and joined by existing investors. Proceeds from the financing will be used to further develop the company's proprietary transistor platform, in order to significantly expand mass manufacturing and further grow Cardea's number of commercial partnerships.

The company's proprietary technology enables ultra-sensitive and direct detection of molecular analytes without requiring normal sample preparations and amplification steps such as polymerase chain reaction (PCR) testing or protein labeling. The technology, says the company, holds the potential for a paradigm shift as it can be developed to perform use case specific multi-omics analysis, such as measuring disease specific nucleic acids, proteins, and small molecules analytes all measured in the same sample at the same time.

An additional new perspective is that it can measure molecular analyte signals over time, allowing the user - or a machine learning algorithm - to interact with the biology while seeing the measurement results live on the screen and learning the molecular signals interdependencies.

"We believe the opportunity of near real-time digital insight to molecular multi-omics is massive and represents a paradigm shift away from the old ways and bottlenecks," says Michael Heltzen, CEO of Cardea. "With a world class team specializing in multi-disciplinary solutions, and after seven years of hard work our graphene-based Cardean transistors and analysis infrastructure is finally ready for product implementation."

The company's Cardean Transistors leverage graphene, a nanomaterial that is biocompatible and a near perfect conductor due to only being one atom thick, in contrast to the common semiconductor material silicon. This enables a signal resolution high enough to listen into live molecular signals and replace optical and static measurements with interactive live-streams of multi-omics signal analysis.

The company's Innovation Partnership Program enables new products and business opportunities via "Powered by Cardea" development partnerships.

Vous êtes certain ?

Si vous désactivez les cookies, vous ne pouvez plus naviguer sur le site.

Vous allez être rediriger vers Google.